KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 in Alzheimer’s disease agitation expected by the end of 2025 Expect to progress next M4 positive allosteric modulator (PAM) program into the
– Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 – Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 – Petosemtamab
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline histology data expected in 1H 2027 and 2028, respectively – -The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) will be unblinded after study completion at Week 52 vs. Week
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million
– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU – – Cash runway expected into Q2 2027 with $420 million in
Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway; on track to initiate APOLLO post-marketing confirmatory trial by mid-2025 Positive update from Phase 1b trial of DISC-0974 in patients with anemia of myelofibrosis (MF) presented at ASH 2024; initial data from ongoing Phase 2 expected in H2 2025
NORTHVILLE, Mich., Feb. 13, 2025 /PRNewswire/ — Cooper-Standard Holdings Inc. (NYSE: CPS) today reported results for the fourth quarter and full year 2024. Fourth Quarter 2024 Summary Sales totaled $660.8 million, a decrease of 1.9% vs. the fourth quarter 2023 Operating income totaled $31.7 million, an increase of $36.2 million vs. the fourth quarter of
Increases net subscriber-add expectations for 2025 significantly to 180-200,000, expecting to reach 2.6 million subscribers by year-end; Increases dividend policy by 25% to $10 million per quarter; AZOUR, Israel, Feb. 26, 2025 /PRNewswire/ — Ituran Location and Control Ltd. (NASDAQ: ITRN) today announced its consolidated financial results for the fourth quarter 2024. Highlights of Full
PURCHASE, NY, Feb. 26, 2025 (GLOBE NEWSWIRE) — Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the full year ended December 31, 2024 (“Full Year 2024”) and three months ended December 31, 2024 (“Fourth Quarter 2024”). Unless otherwise noted, percentage and other changes are relative to the full year
TORONTO, Feb. 25, 2025 (GLOBE NEWSWIRE) — Timbercreek Financial (TSX: TF) (the “Company”) announced today its financial results for the three months and year ended December 31, 2024 (“Q4 2024”). Q4 2024 Highlights1 Significant transaction volume drives portfolio growth: Net mortgage investment portfolio increased by $72.2 million to $1,089.8 million in Q4 2024 as a result